Clinical trials: Astrocytoma, Grade IV
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Newly Diagnosed H3-mutated Glioma
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a non-controlled, open-label, single arm, multicenter phase I trial…
- Trial name
- INTERCEPT-H3 (NCT04808245)
- Testing
- Tecentriq 1200 MG in 20 ML Injection, H3K27M peptide vaccine, Imiquimod (5%)
- Where
- 8 sites in Germany
- Volunteers
- 15 people
- Sponsor
- German Cancer Research Center
Brain and Central Nervous System Tumors
Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas
RATIONALE: Diagnostic procedures, such as positron emission tomography using fluorothymidine F 18, may be effective in finding recurrent disease in patients with gliomas.
- Trial name
- NCT00276770
- Testing
- fluorine F 18 fluorothymidine, positron emission tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Glioma Glioblastoma Multiforme
Functional and Ultrasound Guided Resection of Glioblastoma
Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours
- Trial name
- FUTURE-GB (NCT05399524)
- Testing
- Standard of Care, Additional pre- and intra-operative imaging
- Where
- 24 sites in United Kingdom
- Volunteers
- 357 people
- Sponsor
- University of Oxford
Glioblastoma
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma
- Trial name
- NCT00190424
- Testing
- CpG-ODN
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Adenocarcinoma, Small-cell Lung Cancer
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard)…
- Conditions
- Pancreas Adenocarcinoma, Small-cell Lung Cancer, Glioblastoma, IDH-wildtype
- Trial name
- ROSALIND (NCT06160596)
- Testing
- Long term survival multimodal analysis
- Where
- France
- Volunteers
- 1,020 people
- Sponsor
- Cure 51
Glioblastoma
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating…
- Trial name
- NCT03223103
- Testing
- Poly-ICLC, Tumor Treating Fields, Peptides
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Adilia Hormigo
Brain Cancer
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cabazitaxel that can be given to patients with glioblastoma.
- Trial name
- NCT01740570
- Testing
- Cabazitaxel
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis
Gut Microbiota and Glioblastoma Multiforme Prognosis
Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma.
- Trial name
- NCT03631823
- Testing
- Chemotherapy with temozolomide or no chemotherapy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Refractory Glioblastoma
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma.
- Trial name
- NCT04674527
- Testing
- Elemene, Temozolomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma
Personalized Radiation Therapy for GBM
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival.
- Trial name
- NCT03477513
- Testing
- Radation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00424060
- Testing
- sagopilone, fluorescence in situ hybridization, gene expression analysis
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed…
- Trial name
- NCT03897491
- Testing
- 5-aminolevulinic acid
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- photonamic GmbH & Co. KG
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or…
- Trial name
- NCT00054496
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- The Cleveland Clinic
Glioblastoma, Surgical Margin
Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument
Differentiation between glioma tumor tissue and normal cerebral tissue using Diffuse Reflectance Spectroscopy (DRS) on surgical tissue samples ex-vivo
- Trial name
- NCT05171127
- Testing
- Diffuse Reflectance Spectroscopy
- Where
- Sweden
- Volunteers
- 31 people
- Sponsor
- Karolinska University Hospital
Glioblastoma
Glioblastoma Radiotherapy Using IMRT or Proton Beams
Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are…
- Trial name
- GRIPS (NCT04752280)
- Testing
- Proton irradiation, Photon irradiation
- Where
- 3 sites in Germany
- Volunteers
- 326 people
- Sponsor
- University Hospital Heidelberg
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1)
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
This is a research study in 2 parts assessing the following parameters of the combination of the study drug called bosutinib, and a drug called capecitabine: the safety, how well the subject's body handles the study drug, and…
- Conditions
- Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1)
- Trial name
- NCT00959946
- Testing
- Bosutinib, Capecitabine
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 32 people
- Sponsor
- Pfizer